Jamison Private Wealth Management Inc. Trims Stock Position in Johnson & Johnson (NYSE:JNJ)

Jamison Private Wealth Management Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 87,350 shares of the company's stock after selling 3,187 shares during the period. Johnson & Johnson accounts for approximately 2.2% of Jamison Private Wealth Management Inc.'s investment portfolio, making the stock its 8th biggest position. Jamison Private Wealth Management Inc.'s holdings in Johnson & Johnson were worth $14,486,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rockline Wealth Management LLC lifted its position in shares of Johnson & Johnson by 3.8% in the 1st quarter. Rockline Wealth Management LLC now owns 31,104 shares of the company's stock worth $5,158,000 after purchasing an additional 1,139 shares during the period. Heritage Wealth Management Inc. Texas acquired a new position in Johnson & Johnson in the first quarter valued at $205,000. Advisor Resource Council bought a new stake in Johnson & Johnson during the first quarter valued at $1,273,000. Segment Wealth Management LLC grew its holdings in Johnson & Johnson by 15.9% during the 1st quarter. Segment Wealth Management LLC now owns 3,892 shares of the company's stock worth $645,000 after acquiring an additional 535 shares during the period. Finally, DMKC Advisory Services LLC raised its position in shares of Johnson & Johnson by 1.7% in the 1st quarter. DMKC Advisory Services LLC now owns 11,115 shares of the company's stock worth $1,843,000 after acquiring an additional 185 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on JNJ. Morgan Stanley upped their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Raymond James Financial decreased their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Stock Down 0.6%

JNJ stock opened at $149.81 on Friday. The stock's 50 day moving average is $154.07 and its 200-day moving average is $153.65. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The firm has a market capitalization of $360.44 billion, a PE ratio of 16.66, a P/E/G ratio of 2.27 and a beta of 0.42. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.47%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.